Insomnia News and Research

Latest Insomnia News and Research

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

The U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular safety of rosiglitazone, as presented by the FDA and GlaxoSmithKline. Following this two day discussion, Takeda Pharmaceuticals North America, Inc. ("Takeda") underscores its position that ACTOS (pioglitazone HCl) offers an established safety profile regarding the risk of CV events in people living with type 2 diabetes.

16 Jul 2010

Drugs taken for common medical conditions cause long term cognitive impairment in older adults: Study

Drugs commonly taken for a variety of common medical conditions including insomnia, allergies, or incontinence negatively affect the brain causing long term cognitive impairment in older African-Americans, according to a study appearing in the July 13, 2010 print issue of Neurology, the medical journal of the American Academy of Neurology.

14 Jul 2010

Tart cherry juice could help reduce severity of insomnia in older adults: Study

Drinking tart cherry juice daily could help reduce the severity of insomnia and time spent awake after going to sleep, according to a new study published in the Journal of Medicinal Food.

13 Jul 2010

Reducing chronic pain, dry mouth could improve quality of life in head and neck cancer patients: Study

Head and neck cancer patients who reported poor sleep quality one year after diagnosis had more symptoms of chronic pain and complaints of dry mouth related to radiation treatments, according to a recent study from the University of Michigan Comprehensive Cancer Center.

12 Jul 2010

Shire receives FDA approval of Daytrana for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).

7 Jul 2010

PuraMed BioScience completes clinical study of LipiGesic M for treating acute migraine

PuraMed BioScience, announced today that a clinical study of LipiGesic M has been completed. The study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic™ M for the treatment of acute migraine attacks. The next steps include completion of the manuscript, submission for publication in a peer-reviewed medical journal and actual publication. In an effort to maximize the potential for publication, an embargo has been placed on the disclosure of any of the results of this study.

7 Jul 2010

EC approves change in posology of Circadin from 3 weeks to 3 months of treatment

Neurim Pharmaceuticals confirmed today that the European Commission (EC) has approved a change in treatment duration with Circadin from 3 to 13 weeks (3 months). Circadin is indicated for the treatment of primary insomnia in patients who are aged 55 or over.

6 Jul 2010

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Chelsea Therapeutics International, Ltd. announced the completion and favorable outcome of an independent Data Monitoring Committee (DMC) review of the safety and efficacy data from approximately half the target enrollment in Chelsea's Phase II trial of droxidopa in fibromyalgia.

2 Jul 2010

AstraZeneca announces new support program for patients on ARIMIDEX

AstraZeneca today announced a new patient support program for postmenopausal women with hormone receptor-positive early breast cancer who are prescribed ARIMIDEX. The program is designed to provide eligible patients with instant discounts, potentially saving the patient up to $300.

1 Jul 2010

Forest Laboratories, Gedeon Richter report positive results from radiprodil Phase II study for DPNP pain

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced top-line results from a Phase II placebo and positive comparator-controlled, parallel-arm, double-blind, dose-response clinical trial of the novel, investigational NR2B-selective NMDA (N-methyl D-aspartate) receptor antagonist, radiprodil (RGH-896), for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPNP).

29 Jun 2010

Japan's MHLW grants full marketing authorization to REVLIMID

Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare for use in combination with dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy. This marketing authorization represents the first regulatory approval of REVLIMID in Japan.

25 Jun 2010

Investment report on Somaxon Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Somaxon Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

25 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Study recommends women to avoid drug abuse during prenatal and breastfeeding periods

Give up smoking, do not drink more than three cups of coffee per day, do not take any kind of drug, or if you do, take it as long as possible before feeding your baby. These are some of the recommendations contained in a study produced by Spanish researchers on methods for detecting medicines and drugs in breast milk. The study shows that the risk from substances such as alcohol is still not well understood.

24 Jun 2010

Sleep quality is poor in soldiers with chronic headaches, find researchers

Some 19 percent of soldiers returning from Iraq have migraine and migraine is suspected in another 17 percent. While prevalence of migraine among the U.S. military is well documented , little is known about sleep quality in soldiers with chronic headaches including post-traumatic headache and migraine.

23 Jun 2010

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Affymax, Inc. and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced preliminary top-line results from the Phase 3 clinical program for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients.

21 Jun 2010

Neupro improves wellbeing impaired by pain related to Restless Legs Syndrome

The first data to show that Neupro® (rotigotine transdermal system) significantly improved wellbeing and daily activities that are often impaired by pain related to Restless Legs Syndrome (RLS) were presented this week at the 14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina.

18 Jun 2010

Yoga and meditation in Western medicine

Meditation and deep breathing techniques, as a form of relaxation, have been in use for thousands of years. However, in the unique new book Pranayama (published by AuthorHouse), author Dr. Ravinder Jerath presents explanations and illustrations to more easily and succinctly explain exactly how meditation and deep breathing techniques beneficially affect the human body.

18 Jun 2010

If you suffer from sleep apnea, consult with your dentist: PDA

Sleep apnea, a serious and potentially life-threatening disorder if left untreated, affects approximately 18 million Americans. During sleep apnea episodes, a person stops breathing for at least 10 seconds. Depending on the severity of the disorder, a person can have between 10 and 60 episodes a night. Sleep apnea treatment often involves a team of healthcare providers, including dentists, general physicians, surgeons and sleep specialists.

18 Jun 2010

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Neurocrine Biosciences, Inc. announced today that they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products.

17 Jun 2010

Insomnia News and Research

Latest Insomnia News and Research

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

Drugs taken for common medical conditions cause long term cognitive impairment in older adults: Study

Tart cherry juice could help reduce severity of insomnia in older adults: Study

Reducing chronic pain, dry mouth could improve quality of life in head and neck cancer patients: Study

Shire receives FDA approval of Daytrana for ADHD in adolescents

PuraMed BioScience completes clinical study of LipiGesic M for treating acute migraine

EC approves change in posology of Circadin from 3 weeks to 3 months of treatment

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

AstraZeneca announces new support program for patients on ARIMIDEX

Forest Laboratories, Gedeon Richter report positive results from radiprodil Phase II study for DPNP pain

Japan's MHLW grants full marketing authorization to REVLIMID

Investment report on Somaxon Pharmaceuticals

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Study recommends women to avoid drug abuse during prenatal and breastfeeding periods

Sleep quality is poor in soldiers with chronic headaches, find researchers

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Neupro improves wellbeing impaired by pain related to Restless Legs Syndrome

Yoga and meditation in Western medicine

If you suffer from sleep apnea, consult with your dentist: PDA

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Insomnia News and Research

Latest Insomnia News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in